Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00912340 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase
70
Enrollment target
4
Study locations

NCT00912340 is a Phase 2 study of Breast Cancer that has completed, run by Emory University. The registered enrollment target is 70 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00912340, a Phase 2 study of Breast Cancer, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase
70 participants
Enrollment target
4
Study locations

Study Summary

This phase II trial studies how well everolimus with or without trastuzumab works in treating patients with breast cancer that has not responded to hormone therapy and has spread from where it started to other places in the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, may interfere with the ability of tumor cells to grow and spread. Giving everolimus and adding trastuzumab at the time of disease progression may be an effective treatment for breast cancer.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Everolimus
  • BIOLOGICAL Trastuzumab

Study Locations (4)

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Winship Cancer Institute - Atlanta

Illinois

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago

Wisconsin

  • University of Wisconsin Carbone Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2009-05
Est. Completion 2017-07
Phase Phase 2

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00912340

The ClinicalTrials.gov registry entry for NCT00912340 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Everolimus is the first listed.

NCT00912340 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Illinois, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT00912340 about?

NCT00912340 is a clinical study titled "Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer". This phase II trial studies how well everolimus with or without trastuzumab works in treating patients with breast cancer that has not responded to hormone therapy and has spread from where it started to other places in the body. Everolimus may stop the growth of tumor cells by blocking some of the ...

What is the current status of trial NCT00912340?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2009-05. Estimated completion is 2017-07.

What conditions does trial NCT00912340 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00912340?

The interventions under investigation include: Everolimus (DRUG), Trastuzumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT00912340?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00912340 being conducted?

This trial has 4 study locations across Georgia, Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.